Results 101 to 110 of about 12,862 (201)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability

, 2014
Zeid Kayali,1 Warren N Schmidt2,3 1Division of Gastroenterology and Hepatology, University of Southern California, Los Angeles, CA, USA; 2Department of Internal Medicine and Research Service, Veterans Affairs Medical Center, Iowa City, IA, USA; 3Roy G ...
Schmidt WN, Kayali Z
core  

Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae

, 2017
Zika virus (ZIKV) causes significant public health concerns because of its association with congenital malformations, neurological disorders in adults, and, more recently, death.
Priscila de Paiva Silva, Patrícia A. Reis, Reis, Patricia Alves, Mayara Mattos, Vieira, Yasmine Rangel, Carolina Sacramento, André C. Ferreira, Bozza, Fernando A., Hugo C. de Castro Faria Neto, Silva, Priscila de Paiva, Ferreira, André C., Yasmine Rangel Vieira, Camila Zaverucha-do-Valle, Bozza, Patrícia Torres, Fernando A. Bozza, Sacramento, Carolina, Bozza, Patrícia T., Giselle Barbosa-Lima, Loraine Campanati, Thiago Moreno L. Souza, Souza, Thiago Moreno L., Brüning, Karin, Karin Brüning, Amilcar Tanuri, Faria Neto, Hugo C. de Castro, Tanuri, Amilcar, Mattos, Mayara, Campanati, Loraine, Lima, Giselle Barbosa, Valle, Camila Zaverucha do, Patrícia T. Bozza   +30 more
core   +1 more source

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

, 2017
Blaise K Kutala,1,2 Feryel Mouri,1 Corinne Castelnau,1 Valerie Bouton,1 Nathalie Giuily,1 Nathalie Boyer,1 Tarik Asselah,1,2 Patrick Marcellin1,2 1Service d’hépatologie, Hopital Beaujon-APHP, 2INSERM – University of Paris Diderot ...
Kutala BK, Giuily N, Boyer N, Marcellin P, Castelnau C, Bouton V, Mouri F, Asselah T   +7 more
core  

The reasons for the discontinuation of sofosbuvir/lediprevir.

, 2018
The reasons for the discontinuation of sofosbuvir/lediprevir.
Takeshi Kure (5328974), Tsutomu Tamai (496424), Kazuaki Tabu (496423), Kohei Oda (496422), Takeshi Hori (166759), Akihiro Moriuchi (496425), Masafumi Hashiguchi (5328965), Yukiko Inada (5328971), Kotaro Kumagai (496421), Hirofumi Uto (496418), Yasunari Hiramine (5328956), Seiichi Mawatari (496417), Kunio Fujisaki (5328962), Oki Taniyama (5328968), Sho Ijuin (5328953), Akio Ido (496419), Ai Kasai (5328959)   +16 more
core   +1 more source

Sofosbuvir-based regimens against an “easy” villain: HCV genotype 2

, 2017
Sofosbuvir-based regimens against an “easy” villain: HCV genotype
Angarano, Gioacchino, Annalisa Saracino, Bruno, Giuseppe, Giuseppe Bruno, Milella, Michele, Saracino, Annalisa, Gioacchino Angarano, Michele Milella   +7 more
core   +1 more source

Sofosbuvir : the hepatitis C patients' hope [PDF]

, 2016
Monografia realizada no âmbito da unidade de Estágio Curricular do Mestrado Integrado em Ciências Farmacêuticas, apresentada à Faculdade de Farmácia da Universidade de CoimbraHepatitis C virus infection is a substantial health problem on a global scale. (
Gi, Andreia Filipa Pintor
core  

The SVR12 rates of patients treated with ledipasvir and sofosbuvir.

, 2018
The SVR12 rates of patients treated with ledipasvir and sofosbuvir.
Takeshi Kure (5328974), Tsutomu Tamai (496424), Kazuaki Tabu (496423), Kohei Oda (496422), Takeshi Hori (166759), Akihiro Moriuchi (496425), Masafumi Hashiguchi (5328965), Yukiko Inada (5328971), Kotaro Kumagai (496421), Hirofumi Uto (496418), Yasunari Hiramine (5328956), Seiichi Mawatari (496417), Kunio Fujisaki (5328962), Oki Taniyama (5328968), Sho Ijuin (5328953), Akio Ido (496419), Ai Kasai (5328959)   +16 more
core   +1 more source

Relationship between PPP-adjusted price, GDP per capita, and estimated market size for sofosbuvir and ledipasvir/sofosbuvir.

, 2016
Fig 2 shows the relationship between PPP-adjusted price (y-axis), GDP per capita (USD PPP) (x-axis), and estimated market size (circle size) for (A) sofosbuvir and (B) ledipasvir/sofosbuvir.
Peter Beyer (21528), Kees de Joncheere (3166164), Stefan Wiktor (3166158), Kiu Tay-Teo (3166161), Swathi Iyengar (3166167), Sabine Vogler (3131850), Suzanne Hill (160643)   +6 more
core   +1 more source

Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment

\(\textbf {Background & Aims:}\) In the absence of a hepatitis E virus (HEV)-specific antiviral treatment, sofosbuvir has recently been shown to have antiviral activity against HEV \(\textit {in vivo}\).
Wedemeyer, Heiner (Prof. Dr. med.), Maasoumy, Benjamin (Dr. med.), Nörenberg, Pia, Frericks, Nicola (Dr. rer. nat.), Wißing, Michael Hermann (Ph.D.), Dinkelborg, Katja, Klöhn, Mara (M. Sc.), Jagst, Michelle (Dr. rer. nat.), Behrendt, Elmar Patrick (Dr. med.), Todt, Daniel Matthias (Dr. rer. nat.), Cornberg, Markus (Prof. Dr. med.), Gömer, André Philipp (Dr.), Steinmann, Eike (Prof. Dr. rer. nat.)   +12 more
core   +2 more sources

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

Pakistan Armed Forces Medical Journal, 2020
Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them.
Sumetha Yaseen, Kulsoom Farhat, Mahwish Gul, Syeda Urooj Zaidi, Maryam Saqib, Ayman Zafar   +5 more
doaj